CCL2 and diabetic kidney disease: To date, some studies have explored the expression of MCP-1 in diabetic nephropathy patients and concluded that MCP-1 can influence the level of end-stage renal function in diabetic nephropathy patients; however, the specific exploration of IL-6 and MCP-1 in diabetic nephropathy patients with varying UAER levels is marginally explored [11–13].